Condition: Non-Small Cell Lung Cancer · Sponsor: Henan Genuine Biotech Co., Ltd.
This is an open label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy of Dositinib in participants of locally advanced or metastatic non-small cell lung cancer with positive EGFR mutation.
This description comes directly from the study's public registry record.
Junling Li · +86 138 0117 8891 · drlijunling@vip.163.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Withdrawn |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, China | Recruiting |
| Henan Provincial Cancer Hospital | Zhengzhou, China | Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07231068